FoundationOne CDx test receives FDA approval as companion diagnostic to identify NTRK fusions in solid tumors for Vitrakvi

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The next-generation sequencing-based FoundationOne CDx test has received FDA approval as a companion diagnostic to identify fusions in neurotrophic receptor tyrosine kinase genes, NTRK1, NTRK2, and NTRK3, in DNA isolated from tumor tissue specimens from patients with solid tumors eligible for treatment with Vitrakvi (larotrectinib).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The U.S. Preventive Services Task Force is at risk of losing the expertise, evidence-review infrastructure, and institutional culture that has made it a model for evidence-based medicine. In July 2025, David Ransohoff, a gastroenterologist and clinical epidemiologist in the Division of Gastroenterology and Hepatology at University of North Carolina School of Medicine, noted that HHS...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login